English (United States)|Italiano (Italia)
English (United States) | Italiano (Italia)
Dettaglio articolo
06 settembre 2018 - ITFPHARMA

ITF PHARMA announces FDA approval of TIGLUTIK™ (riluzole) oral suspension for the tratment of amyotrophic lateral sclerosis (ALS)